Drug
Blu 808
Blu 808: highest development phase Phase 2, developed by Blueprint Medicines. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Blueprint Medicines
Trials
| Drug | Phase | Indication |
|---|---|---|
| BLU-808 NCT06931405 | Phase 2 | Chronic Inducible Urticaria |
| BLU-808 NCT06922448 | Phase 2 | Allergic Rhinoconjunctivitis |
| BLU-808 NCT06948032 | Phase 1 | Healthy Participants |
Latest
No recent events.
Follow Blu 808 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.